Emerging Policy Response Resources / Tariffs

Tariff-related Litigation Update – 6/27

Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through June 17, 2025.

Emerging Policy Response Resources / Tariffs

Tariff-related Litigation Update – 6/20

Member-only summary of IEEPA “fentanyl” and reciprocal tariffs under EO 14257, plus status of related legal challenges across federal courts through June 17, 2025.

Emerging Policy Response Resources / Tariffs

Tariff-related Litigation Update

Explore the latest IEEPA tariff developments and legal challenges, including executive orders on fentanyl tariffs and reciprocal duties affecting global MedTech trade.

Cover page of ReedSmith legal briefing on the Supreme Court’s decision in Kennedy v. Braidwood Management, Inc.
Emerging Policy Response Resources / Government & Legislative Affairs

Executive Overview_Kennedy v. Braidwood Management, Inc.

The U.S. Supreme Court is reviewing Braidwood Management v. Becerra, a high-stakes case challenging the authority of the U.S. Preventive Services Task Force (USPSTF) under the Affordable Care Act. At…

Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Tariffs

AdvaMed Testifies in U.S. Senate 

WASHINGTON – Today, President and CEO Scott Whitaker of AdvaMed, the Medtech Association, testified before the U.S. Senate Committee on Finance in its hearing focused on the impact of tariffs…

AdvaMed response letter to OMB’s RFI on deregulation, highlighting support for regulatory reform that fosters medical innovation and improved patient care, dated May 12, 2025.
Emerging Policy Response Resources / Government & Legislative Affairs / Legal

AdvaMed Comments to OMB Deregulation RFI

A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.